(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-0.12% ¥ 8 580.00
Live Chart Being Loaded With Signals
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally...
Stats | |
---|---|
Объем за сегодня | 966 000 |
Средний объем | 0.00 |
Рыночная капитализация | 703.28B |
EPS | ¥0 ( 2024-02-12 ) |
Дата следующего отчета о доходах | ( ¥-12.48 ) 2024-05-08 |
Last Dividend | ¥50.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 83.43 |
ATR14 | ¥533 134 202 (0.23%) |
Объем Корреляция
Taisho Pharmaceutical Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Taisho Pharmaceutical Корреляция - Валюта/Сырье
Taisho Pharmaceutical Финансовые показатели
Annual | 2022 |
Выручка: | ¥301.38B |
Валовая прибыль: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Выручка: | ¥301.38B |
Валовая прибыль: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Выручка: | ¥268.20B |
Валовая прибыль: | ¥163.83B (61.09 %) |
EPS: | ¥161.12 |
FY | 2021 |
Выручка: | ¥282.04B |
Валовая прибыль: | ¥175.99B (62.40 %) |
EPS: | ¥166.84 |
Financial Reports:
No articles found.
Taisho Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥50.00 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥50.00 | 2010-03-29 |
Last Dividend | ¥50.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 27 | -- |
Total Paid Out | ¥1 320.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.76 | -- |
Div. Sustainability Score | 7.14 | |
Div.Growth Potential Score | 2.76 | |
Div. Directional Score | 4.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6638.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
5965.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
4662.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
3902.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3134.T | Ex Dividend Junior | 2024-04-26 | Annually | 0 | 0.00% | |
2004.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8999.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8550.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7872.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7013.T | No Dividend Player | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0263 | 1.500 | 9.47 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00838 | 1.200 | 9.72 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0104 | 1.500 | -0.996 | -1.494 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.04 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 87.55 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.572 | 1.000 | 3.80 | 3.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0590 | 1.000 | -0.819 | -0.819 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.319 | 0.800 | -1.209 | -0.967 | [0.5 - 2] |
Total Score | 7.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 83.52 | 1.000 | 1.665 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0104 | 2.50 | -0.640 | -1.494 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.166 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.428 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.197 | 1.000 | 7.58 | 0 | [0.1 - 0.5] |
Total Score | 2.76 |
Taisho Pharmaceutical
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа